Table 1.
Patients’ characteristics.
| PCa | BPH | Healthy controls | |
|---|---|---|---|
| Patients (n.) | 60 | 80 | 40 |
| Age (years) | 70 ± 5 | 69 ± 5 | 37 ± 4 |
| BMI (kg/m2) | 26.01 ± 1.51 | 26.15 ± 2.15 | 25 ± 1.10 |
| Prebiopsy total PSA value (ng/ml) | |||
| <4 | 4 | 11 | 35 |
| 4–10 | 31 | 33 | 0 |
| >10 | 25 | 36 | 0 |
| Prostate nodule/s at DRE (n. pts) | |||
| Right | 18 | 14 | 0 |
| Left | 10 | 7 | 0 |
| Bilateral | 8 | 4 | 0 |
| Negative | 24 | 55 | 35 |
| Prostate volume at TRUS (ml) | 41.48 ± 11.88 | 53.78 ± 13.30 | 19.23 ± 6.50 |
| PSA density (PSA/volume) | 0.25 ± 0.13 | 0.17 ± 0.07 | 0.05 ± 0.03 |
| Prostate biopsy | YES | YES | NO |
| Low-risk PCa (n.) | 31 | – | – |
| Intermediate-risk PCa (n.) | 9 | – | – |
| High-risk PCa (n.) | 20 | – | – |
| Patients who underwent to prebiopsy mMRI (n.) | 60 | 63 | – |
| Patients with mMRI PIRADS ≥3 (n./%) | 43/71.6 | 28/44.4 | – |
| Patients with mMRI PIRADS ≥4 (n./%) | 15/25 | 2/3.1 | – |
MAD, median absolute deviation.
Descriptive ranges are expressed as (median ± MAD).